Sky-high prices on branded drugs are canceling out any positive effects that increased use of generic drugs has had on containing health care spending, according to a new report from the Blue Cross Blue Shield Association. Generic drugs now make up 83 percent of prescriptions filled in the U.S., up from 82 percent in 2016. However, branded drugs, while only making up 17 percent of total prescriptions filled, account for 79 percent of total spending and have increased 4 percent since 2016. At more than $100 billion, spending on prescription drugs represents over 20 percent of overall health care spending for Blue Cross and Blue Shield commercially insured members. The report, which includes eight years of drug utilization, price changes and overall spending, also provides a list of the top medications by spending during 2017 across the BCBS system. The top three drugs on the list — Humira, Remicade and Enbrel — are each used to treat autoimmune disorders.